

21

9. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate exhibits an X-ray powder diffraction pattern having peaks at diffraction angle 2θ ($^\circ$) of about 6, about 9, about 11, about 13, about 14.5, about 16.5, and about 18 as measured by Cu-K α 1 X-ray powder dif-

10. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate has an X-ray diffraction pattern as shown in FIG. 3.

11. A pharmaceutical composition comprising a crystal-
line monohydrate form of the compound (1-{9-[(4S,2R,3R,
5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-amin-
opurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide that is
substantially free of 2-hydrazinoadenosine; and a pharma-
ceutically acceptable carrier.

12. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate is substantially free of other hydrates or amorphous forms.

13. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate has a purity of at least about 99.6%.

22

14. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate exhibits an X-ray powder diffraction pattern having peaks at diffraction angle 2θ ($^\circ$) of about 6, about 9, about 11, about 13, about 14.5, about 16.5, and about 18 as measured by Cu-K α 1 X-ray powder dif-

15. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate has an X-ray diffraction pattern as shown in FIG. 3.

16. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate is dissolved in the pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising 99.6%
pure (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide dissolved in a pharmaceutically acceptable carrier.

* * * * *